Stock listing
KRX:476060 Onconic Therapeutics, Inc. (온코닉테라퓨틱스) 주가
Follow Onconic Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · KRX:476060
₩10,210 KRW -340 (-3.2%)
Close on Nov 20, 2026
- Day range
- ₩10,150 – ₩10,720 KRWNov 20, 2026
- Volume
- 102,286 sharesNov 20, 2026
- Market cap
- ₩463.6B KRWAt the close on Nov 20, 2026 · price × 45.41M shares outstanding
- 52-week range
- ₩8,790.00 – ₩28,900 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩5.73B KRWMedian day 175,130 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:476060 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩10,210 | -340 | -3.2% | ₩10,500 | ₩10,720 | ₩10,150 | 102,286 | |
| ₩10,550 | +50 | +0.5% | ₩10,600 | ₩11,250 | ₩10,300 | 235,086 | |
| ₩10,500 | -1,500 | -12.5% | ₩11,770 | ₩12,140 | ₩10,500 | 319,772 | |
| ₩12,000 | -570 | -4.5% | ₩12,860 | ₩12,860 | ₩11,990 | 110,096 | |
| ₩12,570 | +270 | +2.2% | ₩12,370 | ₩13,270 | ₩12,370 | 219,349 | |
| ₩12,300 | -240 | -1.9% | ₩12,540 | ₩12,820 | ₩12,130 | 97,961 | |
| ₩12,540 | +440 | +3.6% | ₩12,050 | ₩12,640 | ₩12,050 | 112,649 | |
| ₩12,100 | +490 | +4.2% | ₩11,910 | ₩12,220 | ₩11,890 | 97,113 | |
| ₩11,610 | -70 | -0.6% | ₩11,520 | ₩12,060 | ₩11,470 | 128,534 | |
| ₩11,680 | -390 | -3.2% | ₩11,100 | ₩12,090 | ₩11,100 | 159,995 | |
| ₩12,070 | -60 | -0.5% | ₩12,300 | ₩12,800 | ₩11,980 | 151,878 | |
| ₩12,130 | +330 | +2.8% | ₩11,910 | ₩12,130 | ₩11,400 | 151,734 | |
| ₩11,800 | -590 | -4.8% | ₩12,190 | ₩12,270 | ₩11,700 | 104,397 | |
| ₩12,390 | +280 | +2.3% | ₩11,860 | ₩12,490 | ₩11,830 | 99,458 | |
| ₩12,110 | -510 | -4.0% | ₩12,480 | ₩12,590 | ₩11,950 | 148,190 | |
| ₩12,620 | -450 | -3.4% | ₩13,200 | ₩13,290 | ₩12,520 | 153,329 | |
| ₩13,070 | +300 | +2.3% | ₩12,910 | ₩13,220 | ₩12,910 | 88,044 | |
| ₩12,770 | +420 | +3.4% | ₩12,700 | ₩13,150 | ₩12,700 | 114,466 | |
| ₩12,350 | -590 | -4.6% | ₩12,610 | ₩13,000 | ₩12,350 | 112,742 | |
| ₩12,940 | -130 | -1.0% | ₩12,740 | ₩13,200 | ₩12,600 | 108,427 | |
| ₩13,070 | -700 | -5.1% | ₩13,650 | ₩13,660 | ₩13,030 | 131,981 | |
| ₩13,770 | +180 | +1.3% | ₩13,840 | ₩14,120 | ₩13,670 | 81,321 | |
| ₩13,590 | -270 | -1.9% | ₩14,000 | ₩14,070 | ₩13,300 | 89,135 | |
| ₩13,860 | -40 | -0.3% | ₩13,300 | ₩13,900 | ₩13,300 | 69,968 | |
| ₩13,900 | +1,120 | +8.8% | ₩12,900 | ₩14,160 | ₩12,900 | 178,236 | |
| ₩12,780 | -870 | -6.4% | ₩12,730 | ₩13,030 | ₩12,550 | 191,667 | |
| ₩13,650 | -60 | -0.4% | ₩13,710 | ₩14,020 | ₩13,430 | 119,832 | |
| ₩13,710 | -510 | -3.6% | ₩13,700 | ₩14,010 | ₩13,300 | 192,145 | |
| ₩14,220 | -650 | -4.4% | ₩14,920 | ₩15,170 | ₩14,220 | 160,330 | |
| ₩14,870 | -640 | -4.1% | ₩15,240 | ₩15,290 | ₩14,750 | 177,272 | |
| ₩15,510 | -90 | -0.6% | ₩15,890 | ₩15,940 | ₩15,380 | 157,586 | |
| ₩15,600 | -110 | -0.7% | ₩15,680 | ₩15,910 | ₩14,890 | 165,286 | |
| ₩15,710 | -210 | -1.3% | ₩16,060 | ₩16,160 | ₩15,540 | 174,730 | |
| ₩15,920 | +570 | +3.7% | ₩15,170 | ₩16,000 | ₩15,170 | 310,768 | |
| ₩15,350 | +20 | +0.1% | ₩15,570 | ₩15,720 | ₩15,300 | 157,428 | |
| ₩15,330 | -650 | -4.1% | ₩15,610 | ₩15,670 | ₩15,150 | 242,765 | |
| ₩15,980 | +850 | +5.6% | ₩16,120 | ₩16,430 | ₩15,780 | 604,734 | |
| ₩15,130 | +400 | +2.7% | ₩15,410 | ₩15,590 | ₩14,940 | 372,242 | |
| ₩14,730 | -320 | -2.1% | ₩15,070 | ₩15,140 | ₩14,660 | 163,340 | |
| ₩15,050 | +190 | +1.3% | ₩14,970 | ₩15,320 | ₩14,840 | 141,480 | |
| ₩14,860 | -260 | -1.7% | ₩15,360 | ₩15,380 | ₩14,800 | 175,530 | |
| ₩15,120 | +520 | +3.6% | ₩14,540 | ₩15,320 | ₩14,540 | 231,321 | |
| ₩14,600 | -100 | -0.7% | ₩14,660 | ₩14,740 | ₩14,420 | 103,952 | |
| ₩14,700 | +70 | +0.5% | ₩14,750 | ₩15,600 | ₩14,610 | 368,440 | |
| ₩14,630 | -320 | -2.1% | ₩14,690 | ₩14,990 | ₩14,450 | 291,895 | |
| ₩14,950 | -670 | -4.3% | ₩15,220 | ₩15,460 | ₩14,950 | 221,353 | |
| ₩15,620 | -470 | -2.9% | ₩16,010 | ₩16,070 | ₩15,380 | 261,102 | |
| ₩16,090 | +40 | +0.2% | ₩15,760 | ₩16,310 | ₩15,670 | 270,295 | |
| ₩16,050 | -240 | -1.5% | ₩16,340 | ₩16,420 | ₩16,000 | 258,389 | |
| ₩16,290 | -150 | -0.9% | ₩16,250 | ₩16,390 | ₩16,010 | 295,382 | |
| ₩16,440 | -670 | -3.9% | ₩16,800 | ₩16,960 | ₩16,140 | 475,310 | |
| ₩17,110 | +310 | +1.8% | ₩17,100 | ₩17,580 | ₩16,530 | 822,021 | |
| ₩16,800 | -1,190 | -6.6% | ₩17,560 | ₩17,820 | ₩16,800 | 673,839 | |
| ₩17,990 | -40 | -0.2% | ₩17,430 | ₩18,440 | ₩16,900 | 2,945,540 | |
| ₩18,030 | +3,260 | +22.1% | ₩15,200 | ₩18,620 | ₩14,850 | 6,389,230 | |
| ₩14,770 | +400 | +2.8% | ₩14,400 | ₩14,880 | ₩14,260 | 262,751 | |
| ₩14,370 | -90 | -0.6% | ₩14,380 | ₩14,600 | ₩14,190 | 123,532 | |
| ₩14,460 | +90 | +0.6% | ₩14,700 | ₩14,900 | ₩14,400 | 188,581 | |
| ₩14,370 | -150 | -1.0% | ₩14,150 | ₩14,400 | ₩13,820 | 176,015 | |
| ₩14,520 | 0 | 0.0% | ₩14,550 | ₩14,760 | ₩14,220 | 228,054 | |
| ₩14,520 | -210 | -1.4% | ₩14,930 | ₩14,940 | ₩14,170 | 376,814 | |
| ₩14,730 | +730 | +5.2% | ₩14,830 | ₩15,090 | ₩14,230 | 324,140 |
Splits
1 split · KRX:476060 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 4-for-1 | Split |
- Ticker
- KRX:476060
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
Latest news
Onconic Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in all · newest Oct 30, 2025 · oldest 2025
Valuation
P/E 19.1× against a median of 11.8×: the highest of 3 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩401.0B KRW
- P/E
- 19.1×
- EV/sales
- 4.9×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 5.4×
- Gross margin
- 100.0%
- Operating margin
- 21.1%
- Net margin
- 29.5%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Onconic Therapeutics, Inc. · KRX:476060 | US$346.5M | US$299.7M | 19.1× | 4.9× | n/a | 5.4× | 29.5% | 0.0× | n/a |
| Puma Biotechnology Inc · NASDAQ:PBYI | US$364.5M | US$255.9M | 15.3× | 1.1× | 5.8× | 2.5× | 10.3% | 0.0× | 0.88 |
| PureTech Health PLC · LSE:PRTC | US$364.3M | US$160.3M | n/a | 34.4× | n/a | 0.9× | n/a | 0.1× | n/a |
| Lumosa Therapeutics Co Ltd · TPEX:6535 | US$362.3M | US$343.1M | n/a | 329× | n/a | 9.7× | n/a | 0.0× | n/a |
| Aspen Neuroscience, Inc. · NASDAQ:ASPE | US$361.2M | US$288.8M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| AbClon, Inc. · KRX:174900 | US$348.2M | US$321.1M | n/a | 80.9× | n/a | 8.8× | −328.3% | 0.0× | n/a |
| Alector, Inc. · NASDAQ:ALEC | US$347.6M | US$208.9M | 8.4× | 1.2× | 4.9× | 3.0× | 23.9% | 0.0× | 1.72 |
| Gongwin Biopharm Holdings Co., Ltd. · TPEX:6617 | US$347.3M | US$296.6M | n/a | 232× | n/a | 4.9× | −389.6% | 0.0× | n/a |
| Lyell Immunopharma, Inc. · NASDAQ:LYEL | US$339.3M | US$196.5M | n/a | 13,099× | n/a | 1.8× | n/a | 0.2× | 1.51 |
| Avacta Group PLC · LSE:AVCT | US$337.8M | US$337.2M | n/a | 2,281× | n/a | 68.5× | n/a | 5.3× | n/a |
| Inovio Pharmaceuticals, Inc. · NASDAQ:INO | US$329.7M | US$7.56B | n/a | 25,303× | 3.4× | n/a | n/a | n/a | 0.70 |
| Median of the others | US$347.9M | US$292.7M | 11.8× | 232× | 4.9× | 4.0× | −159.0% | 0.0× | 1.20 |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 53.4B | 14.8B | 21.1B | 95.0M |
| Gross profit | 53.4B | 14.8B | 21.1B | 95.0M |
| Research and development | 9.72B | 10.9B | 15.8B | 13.2B |
| Selling, general and administrative | 28.2B | 6.14B | 1.20B | 492.0M |
| Operating income | 12.6B | -4.80B | 2.23B | -14.8B |
| Depreciation and amortization | 528.4M | 452.7M | 460.1M | 200.8M |
| EBITDA | 13.1B | -4.35B | 2.69B | -14.6B |
| Interest expense | 11.7M | 664.2M | 1.78B | 904.4M |
| Income before tax | 13.7B | -9.94B | 661.8M | -14.4B |
| Net income | 15.8B | -8.09B | 1.68B | -14.4B |
| Earnings per share, basic | 355.12 | -749.04 | 155.73 | -1,335.80 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 47.0B | 43.0B | 30.1B | 27.3B |
| Short-term investments | 5.69B | |||
| Receivables | 10.5B | 7.33B | 104.5M | |
| Current assets | 63.8B | 52.1B | 30.8B | 28.2B |
| Total assets | 75.7B | 60.9B | 37.5B | 30.9B |
| Accounts payable | 2.67B | 708.7M | ||
| Current liabilities | 3.62B | 4.77B | 57.0B | 26.6B |
| Total liabilities | 3.67B | 4.89B | 57.2B | 52.8B |
| Shareholders' equity | 72.0B | 56.0B | -19.7B | -21.9B |
| Shares outstanding | 44.4M | 10.8M | 10.8M | 10.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | 11.4B | -7.84B | 4.14B | -15.0B |
| Capital spending | -302.9M | -141.3M | -1.16B | -2.58B |
| Free cash flow | 11.1B | -7.98B | 2.98B | -17.5B |
| Change in cash | 4.05B | 12.9B | 2.78B | 8.46B |
Cap table
Built by 6ix from Onconic Therapeutics, Inc.’s releases
- Common shares
- 45,407,840
- Fully diluted
- 45,407,840
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 45,407,840 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 45,407,840 |
Log in to ask 6ix AI your own questions about Onconic Therapeutics, Inc.